69591-19-1

Basic information

• Product Name: (6-chloropyrimidin-4-yl)phenylamine
• Synonyms: (6-chloropyrimidin-4-yl)phenylamine
• CAS NO: 69591-19-1
• Molecular Formula: C₁₀H₈ClN₃
• Molecular Weight: 206
• Mol File: 69591-19-1.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (6-chloropyrimidin-4-yl)phenylamine(CAS DataBase Reference)
• NIST Chemistry Reference: (6-chloropyrimidin-4-yl)phenylamine(69591-19-1)
• EPA Substance Registry System: (6-chloropyrimidin-4-yl)phenylamine(69591-19-1)

Safety Data

• Hazardous Substances Data: 69591-19-1(Hazardous Substances Data)

Usage

Uses

6-chloro-N-phenylpyrimidin-4-amine is a useful research chemical.

Upstream product

• 17466-00-1 7-chloro-3-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine 
• 99185-53-2 6-anilino-3H-pyrimidin-4-one 
• 1193-21-1 4,6-dichloropyrimidine 
• 62-53-3 aniline 

Downstream Products

• 607723-65-9 2-{methyl[6-(phenylamino)pyrimidin-4-yl]amino}ethanol 
• 1020536-65-5 6-(2-fluoro-4-nitrophenoxy)-N-phenylpyrimidin-4-amine 
• 607723-83-1 4-(2-{methyl[6-(phenylamino)pyrimidin-4-yl]amino}ethoxy)benzaldehyde 

Relevant articles and documents

Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors

Vascular endothelial growth factor receptor-2 (VEGFR-2) plays a crucial role in tumor angiogenesis, and inhibition of the VEGFR-2 signaling pathway has already become an attractive approach for cancer therapy. In this study, a novel pyrimidine-based derivative 7j was designed as lead compound, and three series of potent VEGFR-2 inhibitors were synthesized and biologically evaluated against A549 and HepG2 cell lines. Compounds 7d, 9s and 13n exhibited superior inhibitory activities against A549 cell with IC50 ranged from 9.19 to 13.17 μM and HepG2 cell with IC50 ranged from 11.94 to 18.21 μM compared to those of Pazopanib (IC50 = 21.18 and 36.66 μM). In addition, molecular docking study was performed to investigate the binding capacity and binding mode between target compounds and VEGFR-2.

Synthesis and biological evaluation of 4-(2-fluorophenoxy)-3,3′-bipyridine derivatives as potential c-met inhibitors

Six series of novel 4-(2-fluorophenoxy)-3,3′-bipyridine derivatives conjugated with aza-aryl formamide/amine scaffords were designed and synthesized through a structure-based molecular hybridization approach. The target compounds were evaluated for c-Met kinase inhibitory activities and cytotoxicity against four cancer cell lines (HT-29, A549, MKN-45 and MDA-MB-231) in vitro. Most compounds exhibited moderate to excellent potency, and the most promising candidate 26c (c-Met kinase IC50 = 8.2 nM) showed a 4.7-fold increase in cytotoxicity against c-Met-addicted MKN-45 cell line in vitro (IC50 = 3 nM), superior to that of Foretinib (IC50 = 23 nM). The preliminary structure-activity relationship indicated that a 1H-benzo [e] [1,3,4]thiadiazine-3-carboxamide-4,4-dioxide moiety as linker contributed to the antitumor potency.

KINASE INHIBITORS AND USES THEREOF

The present invention relates to compounds of the general formula (A) and pharmaceutical compositions thereof that inhibit protein tyrosine activity. In particular the invention relates to said compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signalling, for example, the inhibition of VEGF receptor signalling and HGF receptor signalling. Said compounds and compositions are useful for the treatment of cell proliferative diseases and conditions.